Triple-Negative Breast Cancer: Unique Biology and Its Management

REFERENCES

• Jemal, A.; Siegel, R.; Ward, E.; Hao, Y.; Xu, J.; Murray, T.; Thun, M.J. Cancer statistics, 2008. CA Cancer J Clin 2008, 58(2), 71–96.
   PubMed Web of Science ®Google Scholar
• Cleator, S.; Heller, W.; Coombes, R. Triple-negative breast cancer: therapeutic options. Lancet Oncol 2007, 3, 235–244.
   Google Scholar
• Nielsen, T.; Hsu, F.; Jensen, K.; Cheang, M.; Karaca, G.; Hu, Z.; Hernandez-Boussard, T.; Livasy, C.; Cowan, D.; Dressler, L.; Akslen, L.A.; Ragaz, J.; Gown, A.M.; Gilks, C.B.; van de Rijn, M.; Perou, C.M. Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res 2004, 10, 5367–5374.
   PubMed Web of Science ®Google Scholar
• Perou, C.M.; Sorlie, T.; Eisen, M.B.; van de Rijn, M.; Jeffrey, S.S.; Rees, C.A.; Pollack, J.R.; Ross D.T.; Johnsen, H.; Akslen, L.A.; Fluge, O.; Pergamenschikov, A.; Williams, C.; Zhu, S.X.; Lønning, P.E.; Børresen-Dale, A.L.; Brown, P.O.; Botstein, D. Molecular portraits of human breast tumours. Nature 2000, 406, 747–752.
   PubMed Web of Science ®Google Scholar
• Sotiriou, C.; Neo, S.Y.; McShane, L.M.; Korn, E.L.; Long, P.M.; Jazaeri, A.; Martiat, P.; Fox, S.B.; Harris, A.L.; Liu, E.T. Breast cancer classification and prognosis based on gene expression profiles from a population-based study. Proc Natl Acad Sci 2003, 100(18), 10393–10398.
   PubMed Web of Science ®Google Scholar
• Lakhani, S.; Reis-Filho, J.; Fulford, L.; Penault-Llorca, F.; Van Der Vijver, M.; Parry, S.; Bishop, T.; Benitez, J.; Rivas, C.; Bignon, Y.J.; Chang-Claude, J.; Hamann, U.; Cornelisse, C.J.; Devilee, P.; Beckmann, M.W.; Nestle-Krämling, C.; Daly, P.A.; Haites, N.; Varley, J.; Lalloo, F.; Evans, G.; Maugard, C.; Meijers-Heijboer, H.; Klijn, J.G.; Olah, E.; Gusterson, B.A.; Pilotti, S.; Radice, P.; Scherneck, S.; Sobol, H.; Jacquemier, J.; Wagner, T.; Peto, J.; Stratton, M.R.; McGuffog, L.; Easton, D.F. Breast Cancer Linkage Consortium: prediction of BRCA1 status in patients with breast cancer using estrogen receptor and basal phenotype. Clin Cancer Res 2005, 11, 5175–5180.
   PubMed Web of Science ®Google Scholar
• James, C.; Quinn, J.; Mullan, P.; Johnston, P.G.; Harkin, D.P. BRCA1, a potential predictive biomarker in the treatment of breast cancer. The Oncologist 2007, 12, 142–150.
   PubMed Web of Science ®Google Scholar
• Turner, N.C.; Reis-Filho, J.S.; Russell, A.M.; Springall, R.J.; Ryder, K.; Steele, D.; Savage, K.; Gillett, C.E.; Schmitt, F.C.; Ashworth, A.; Tutt, A.N. BRCA1 dysfunction in sporadic basal-like breast cancer. Oncogene 2007, 26(14), 2126–2132.
   PubMed Web of Science ®Google Scholar
• Yang, Q.; Sakurai, T.; Mori, I.; Yoshimura, G.; Nakamura, M.; Nakamura, Y.; Suzuma, T.; Tamaki, T.; Umemura, T.; Kakudo, K. Prognostic significance of BRCA1 expression in Japanese sporadic breast carcinomas. Cancer 2001, 92, 54–60.
   PubMed Web of Science ®Google Scholar
• Rhee, J.; Han, S.W.; Oh, D.Y.; Kim, J.H.; Im, S.A.; Han, W.; Park, I.A.; Noh, D.Y.; Bang, Y.J.; Kim, T.Y. The clinicopathologic characteristics and prognostic significance of triple-negativity in node-negative breast cancer. BMC Cancer 2008, 8, 307.
   PubMed Web of Science ®Google Scholar
• Rakha, E.A.; El-Sayed, M.E.; Green, A.R.; Lee, A.H.; Robertson, J.F.; Ellis, I.O. Prognostic markers in triple-negative breast cancer. Cancer 2007, 109, 25–32.
   PubMed Web of Science ®Google Scholar
• Carey, L.; Perou, C.; Livasy, C.; Dressler, L.G.; Cowan, D.; Conway, K.; Karaca, G.; Troester, M.A.; Tse, C.K.; Edmiston, S.; Deming, S.L.; Geradts, J.; Cheang, M.C.; Nielsen, T.O.; Moorman, P.G.; Earp, H.S.; Millikan, R.C. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA 2006, 295, 2492–2502.
   PubMed Web of Science ®Google Scholar
• Chae, B.J.; Bae, J.S.; Lee, A.; Park, W.C.; Seo, Y.J.; Song, B.J.; Kim, J.S.; Jung, S.S. p53 as a specific prognostic factor in triple-negative breast cancer. Jpn J Clin Oncol 2009, 39, 217–224.
   PubMed Web of Science ®Google Scholar
• Livasy, C.; Karaca, G.; Nanda, R.; Tretiakova, M.S.; Olopade, O.I.; Moore, D.T.; Perou, C.M. Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma. Mod Pathol 2006, 19, 264–271.
   PubMed Web of Science ®Google Scholar
• Dent, R.; Trudeau, M.; Pritchard, K.I.; Hanna, W.M.; Kahn, H.K.; Sawka, C.A.; Lickley, L.A.; Rawlinson, E.; Sun, P.; Narod, S.A. Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res 2007, 13, 4429–4434.
   PubMed Web of Science ®Google Scholar
• Mersin, H.; Yildirim, E.; Berberoglu, U. The prognostic importance of triple negative breast carcinoma. Breast 2008, 7(4), 341–346
   Google Scholar
• Schneider, B.P.; Winer, E.P.; Foulkes, W.D.; Garber, J.; Perou, C.M.; Richardson, A.; Sledge, G.W.; Carey, L.A. Triple-negative breast cancer: risk factors to potential targets. Clin Cancer Res 2008, 14, 8010–8018.
   PubMed Web of Science ®Google Scholar
• Gluz, O.; Nitz, U.A.; Harbeck, N.; Ting, E.; Kates, R.; Herr, A.; Lindemann, W.; Jackisch, C.; Berdel, W.E.; Kirchner, H.; Metzner, B.; Werner, F.; Schütt, G.; Frick, M.; Poremba, C.; Diallo-Danebrock, R.; Mohrmann, S.; West German Study Group. Triple-negative high-risk breast cancer derives particular benefit from dose intensification of adjuvant chemotherapy: results of WSG AM-01 trial. Ann Oncol 2008, 19(5), 861–870.
   PubMed Web of Science ®Google Scholar
• Rouzier, R.; Perou, C.; Symmans, W.; Ibrahim, N.; Cristofanilli, M.; Anderson, K.; Hess, K.R.; Stec, J.; Ayers, M.; Wagner, P.; Morandi, P.; Fan, C.; Rabiul, I.; Ross, J.S.; Hortobagyi, G.N.; Pusztai, L. Breast cancer molecular subtypes respond differently to preoperative chemotherapy. Clin Cancer Res 2005, 11, 5678–5685.
   PubMed Web of Science ®Google Scholar
• Liedtke, C.; Mazouni, C.; Hess, K.; André, F.; Tordai, A.; Mejia, J.A.; Symmans, W.F.; Gonzalez-Angulo, A.M.; Hennessy, B.; Green, M.; Cristofanilli, M.; Hortobagyi, G.N.; Pusztai, L. Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J Clin Oncol 2008, 26, 1275–1281.
   PubMed Web of Science ®Google Scholar
• Di Leo, A.; Isola, J.; Piette, F.; Ejlertsen, B.; Pritchard, K.I.; Bartlett, J.M.; Desmedt, C.; Larsimont, D.; Tanner, M.; Mouridsen, H.; O’Malley, F.P.; Twelves, C.; Cardoso, F.; Poole, C.J.; Piccart, M.J.; Buyse, M.E. A meta-analysis of phase III trials evaluating the predictive value of HER2 and topoisomerase II alpha in early breast cancer patients treated with CMF or anthracycline-based adjuvant therapy. Cancer Res 2009, 69, (abstr 705).
   Web of Science ®Google Scholar
• Carey, L.A.; Rugo, H.S.; Marcom, P.K.; Irvin, W.; Ferraro, M.; Burrows, E.; He, X.; Perou, C.M.; Winer, E.P; on behalf of the Translational Breast Cancer Research Consortium TBCRC 001. EGFR inhibition with cetuximab added to carboplatin in metastatic triple-negative (basal-like) breast cancer. . J Clin Oncol 2008, 26(15S), 43s (abstr 1009).
   Google Scholar
• Dickler, M.N.; Cobleigh, M.A.; Miller, K.D.; Klein, P.M.; Winer, E.P. Efficacy and safety of erlotinib in patients with locally advanced or metastatic breast cancer. Breast Cancer Res Treat 2009, 115(1), 115–121.
   PubMed Web of Science ®Google Scholar
• Miller, K.; Wang, M.; Gralow, J.; Dickler, M.; Cobleigh, M.; Perez, E.A.; Shenkier, T.; Cella, D.; Davidson, N.E. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 2007, 357, 2666–2676.
   PubMed Web of Science ®Google Scholar
• Burstein, H.; Elias, A.; Rugo, H.; Cobleigh, M.A.; Wolff, A.C.; Eisenberg, P.D.; Lehman, M.; Adams, B.J.; Bello, C.L.; DePrimo,S.E.; Baum, C.M.; Miller, K.D. Phase II study of sunitinib malate, an oral multi-targeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. J Clin Oncol 2008, 26, 1810–1816.
   PubMed Web of Science ®Google Scholar
• Barrios, C.; Liu, M.-C.; Lee, S.C.; Vanlemmens, L.; Ferrero, J.-M.; Tabei, T.; Pivot, X.; Iwata, H.; Aogi, K.; Brickman, M.; Zhang, K.; Kern, K.; Martin, M. Phase III Randomized trial of sunitinib (SU) vs. capecitabine (C) in patients (Pts) with previously treated HER2-negative advanced breast cancer (ABC). Cancer Res 2009, 69, 24 (suppl; abstr 46).
   Google Scholar
• Farmer, H.; McCabe, N.; Lord, C.J.; Tutt, A.N.; Johnson, D.A.; Richardson, T.B.; Santarosa, M.; Dillon, K.J.; Hickson, I.; Knights, C.; Martin, N.M.; Jackson, S.P.; Smith, G.C.; Ashworth, A. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 2005, 434, 917–921.
   PubMed Web of Science ®Google Scholar
• O’Shaughnessy, J.; Osborne, C.; Pippen, J.; Yoffe, M.; Patt, D.; Monaghan, G.; Rocha, C.; Ossovskaya, V.; Sherman, B.; Bradley, C. Efficacy of BSI-201, a poly (ADP-ribose) polymerase-1 (PARP1) inhibitor, in combination with gemcitabine/carboplatin (G/C) in patients with metastatic triple-negative breast cancer (TNBC): results of a randomized phase II trial. J Clin Oncol 2009, 27, 18s, (suppl; abstr 3).
   Google Scholar
• Loesch, D.; Asmar, L.; McIntyre, K.; Doane, L.; Monticelli, M.; Paul, D.; Vukelja, S.; Orlando, M.; Vaughn, L.G.; Zhan, F.; Boehm, K.A.; O’Shaughnessy, J. Phase II trial of gemcitabine/carboplatin (plus trastuzumab in HER2-positive disease) in patients with metastatic breast cancer. Clin Breast Cancer 2008, 8, 178–186.
   PubMed Web of Science ®Google Scholar
• Fong, P.C.; Boss, D.S.; Yap, T.A.; Tutt, A.; Wu, P.; Mergui-Roelvink, M.; Mortimer, P.; Swaisland, H.; Lau, A.; O’Connor, M.J.; Ashworth, A.; Carmichael, J.; Kaye, S.B.; Schellens, J.H.; de Bono, J.S. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med 2009, 361, 123–134.
   PubMed Web of Science ®Google Scholar
• Tutt, A.; Robson, M.; Garber, J.E.; Domchek, S.; Audeh, M.W.; Weitzel, J.N.; Friedlander, J.M.; Carmichael, J. Phase II trial of the oral PARP inhibitor olaparib in BRCA-deficient advanced breast cancer. J Clin Oncol 2009, 27, 18s, (suppl; abstr CRA501).
   Google Scholar
• Finn, R.S.; Dering, J.; Ginther, C.; Wilson, C.A.; Glaspy, P.; Tchekmedyian, N.; Slamon, D.J. Dasatinib, an orally active small molecule inhibitor of both the src and abl kinases, selectively inhibits growth of basal-type/“triple-negative” breast cancer cell lines growing in vitro. Breast Cancer Res Treat 2007, 105, 319–326.
   PubMed Web of Science ®Google Scholar
• Finn, R.S.; Bengala, C.; Ibrahim, N.; Strauss, L.C.; Fairchild, J.; Sy, O.; Roche, H.; Sparano, J.; Goldstein, L.J. Phase II trial of dasatinib in triple-negative breast cancer: results of study CA180059. Cancer Res 2009, 69, 242s (suppl. abstr 3118).
   Google Scholar
• Saal, L.H.; Holm, K.; Maurer, M.; Memeo, L.; Su, T.; Wang, X.; Yu, J.S.; Malmström, P.O.; Mansukhani, M.; Enoksson, J.; Hibshoosh, H.; Borg, A.; Parsons, R. PIK3CA mutations correlate with hormone receptors, node metastasis, and ERBB2, and are mutually exclusive with PTEN loss in human breast carcinoma. Cancer Res 2005, 65, 2554–2559.
   PubMed Web of Science ®Google Scholar